



(51) International Patent Classification:

C12N 15/113 (2010.01) C12N 9/22 (2006.01)

(21) International Application Number:

PCT/US2021/022840

(22) International Filing Date:

17 March 2021 (17.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/991,403 18 March 2020 (18.03.2020) US

(71) Applicant: SCRIBE THERAPEUTICS INC. [US/US];
1150 Marina Village Parkway, Alameda, California 94501 (US).

(72) Inventors: OAKES, Benjamin; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). SPINNER, Hannah; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). DENNY, Sarah; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). STAAHL, Brett T.; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). TAYLOR, Kian; c/o Scribe Therapeutics Inc., 1150


Marina Village Parkway, Alameda, California 94501 (US). **BANEY, Katherine**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **COLIN, Isabel**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **ADIL, Maroof**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **URNES, Cole**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **HIGGINS, Sean**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US).

(74) Agent: CANDE, Jessica et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: COMPOSITIONS AND METHODS FOR THE TARGETING OF C9ORF72

FIG. 24 Mutation position distribution



(57) Abstract: Provided herein are Class 2 Type V systems comprising nucleases, guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a *C9orf72* gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations or duplications in the *C9orf72* gene. Also provided are methods of using such systems to modify cells having such mutations or duplications.

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*